147
Participants
Start Date
June 4, 2014
Primary Completion Date
May 5, 2016
Study Completion Date
September 14, 2016
Riociguat (Adempas, BAY63-2521)
Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
Placebo
Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
Auckland
Geneva
Buenos Aires
Darlinghurst
Camperdown
Sydney
Leuven
Bern
Prahran
San Miguel de Tucumán
Chermside
Porto
Adelaide
Godoy Cruz
Murdoch
Christchurch
Zurich
Aarhus N
Columbia University Medical Center, New York
Riyadh
Riyadh
Riyadh
Athens
Haidari
Marseille
Pittsburgh
Denizli
Monza-Brianza
Falls Church
Großhansdorf
Durham
Hanover
Orlando
Miami
Izmir
Giessen
Louisville
Columbus
Cleveland
Cincinnati
Essen
Ioannina
Valencia
Forlì-Cesena
Siena
Lille
Via Christi Clinic, Wichita
Bron
Paris
Aurora
München
München
University of California, Los Angeles, Los Angeles
Palermo
Jerusalem
San Francisco
Würzburg
Portland
Moscow
Moscow
Saint Petersburg
Vladimir
Haifa
Petah Tikva
Ramat Gan
Nashville
Dallas
Mar del Plata
Bogotá
Floridablanca-Bucaramanga
Santiago de Cali
Bogotá
Buenos Aires
Vancouver
Ottawa
Toronto
Québec
Dresden
Thessaloniki
Rome
Seto
Yokohama
Sakai
Shibuya-ku
Chiba
Coimbra
Vila Nova de Gaia
Barcelona
Barcelona
Cambridge
Clydebank
London
Newcastle
Lead Sponsor
Bayer
INDUSTRY